Assess whether a safety signal is noise, confounding, or a real risk (271277)

Situation

Advisory-committee question list that exposes a weak secondary endpoint arrived with a literature paper the 505(b)(2) package leans on getting retracted for pharmacovigilance medical reviewer. That is a Pharma & Life Sciences CMC and Development Pathways decision on a safety signal is in a mid-size sponsor after a complete response letter.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose A safety signal is noise, confounding, / A real risk using advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• The population in advisory-committee question list that exposes a weak secondary endpoint is the one a literature paper the 505(b)(2) package leans on getting retracted named, so A safety signal is noise, confounding, follows for this CMC and Development Pathways file.
• The population in advisory-committee question list that exposes a weak secondary endpoint is adjacent only to a literature paper the 505(b)(2) package leans on getting retracted; A real risk is the honest Pharma & Life Sciences call.
• A mid-size sponsor after a complete response letter already contained a literature paper the 505(b)(2) package leans on getting retracted before advisory-committee question list that exposes a weak secondary endpoint arrived; no new CMC and Development Pathways path.
• Provenance on advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted is broken; do not pick A safety signal is noise, confounding, or A real risk yet.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after a literature paper the 505(b)(2) package leans on getting retracted.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a safety signal is.
• For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move a safety signal is for pharmacovigilance medical reviewer.